SCHEMBL6492509

SCHEMBL6492509

CC(=O)NCCN1CCc2cc(NC(=O)C3=C(c4ccc(C)cc4)CCCC3)ccc2C1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PLAU P00749 1/20 0.47
▸ SIGMAR1 Q99720 2/20 0.46
▸ DRD2 P14416 1/20 0.46
▸ DRD3 P35462 1/20 0.46
▸ USP2 O75604 1/20 0.46
▸ TAAR1 Q96RJ0 1/20 0.46
▸ SMN1; SMN2 Q16637 2/20 0.43
▸ MEN1 O00255 2/20 0.43
▸ KMT2A Q03164 2/20 0.43
▸ LMNA P02545 2/20 0.43
▸ TMPRSS2 O15393 1/20 0.43
▸ NOD1 Q9Y239 1/20 0.43
▸ TP53 P04637 1/20 0.43
▸ ALOX15 P16050 1/20 0.43
▸ MAPT P10636 2/20 0.42
▸ ALDH1A1 P00352 2/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ NFKB1 P19838 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ NFKB2 Q00653 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6501693 0.92 MEN1 (0.54) PLAUSIGMAR1DRD2DRD3MEN1
SCHEMBL6491779 0.90 ACACB (0.43) MEN1KMT2ATP53ALOX15HSP90AA1
SCHEMBL20909873 0.79 SIGMAR1 (0.58) SIGMAR1DRD2DRD3USP2TAAR1
SCHEMBL6648762 0.77 SIGMAR1 (0.52) PLAUSIGMAR1DRD2DRD3USP2
SCHEMBL6649528 0.75 MEN1 (0.48) SIGMAR1USP2TAAR1SMN1; SMN2MEN1
SCHEMBL22549230 0.74 SIGMAR1 (0.58) SIGMAR1DRD2DRD3USP2TAAR1
SCHEMBL6489620 0.74 ABCB1 (0.51) DRD2NOD1
SCHEMBL6501845 0.74 NOD1 (0.47) PLAUSMN1; SMN2MEN1KMT2ALMNA
SCHEMBL691418 0.73 MTTP (0.59) SMN1; SMN2LMNAMAPTALDH1A1KDM4E
SCHEMBL6496773 0.73 ABCB1 (0.40) NOD1ITGB3ITGA2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors DAISO CO., LTD. (JP) 2005-02-17 — — US disclosed
EP-1472226-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2004-11-03 — — EP disclosed
WO-2003045921-A1 HETEROCYCLIC AMIDE COMPOUNDS AS APOLIPOPROTEIN B INHIBITORS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 2003-06-05 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050038035-A1 Heterocyclic amide compounds as apolipoprotein b inhibitors APOB, APOL1, CTRB2 PLAU 2176/4885SIGMAR1 792/4885DRD2 2927/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback